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Abstract
Purpose: To report the treatment results and prognostic factors of childhood patients with Hodgkin's
disease treated with chemotherapy (CT) followed by low dose radiotherapy (RT).
Patients and methods: This retrospective series analyzed 166 patients under 18 years old, treated from
January 1985 to December 2003. Median age was 10 years (range 2–18). The male to female ratio was 2,3
: 1. Lymphonode enlargement was the most frequent clinical manifestation (68%), and the time of symptom
duration was less than 6 months in 55% of the patients. In histological analysis Nodular Sclerosis was the
most prevalent type (48%) followed by Mixed Celularity (34.6%). The staging group according Ann Arbor
classification was: I (11.7%), II (36.4%), III (32.1%) and IV (19.8%). The standard treatment consisted of
chemotherapy multiple drug combination according the period of treatment protocols vigent: ABVD in
39% (n-65) of the cases, by VEEP in 13 %(n-22), MOPP in 13 %(n-22), OPPA-13 %(n-22) and ABVD/OPPA
in 22 %(n-33). Radiotherapy was device to all areas of initial presentation of disease. Dose less or equal
than 21 Gy was used in 90.2% of patients with most part of them (90%) by involved field (IFRT) or mantle
field.
Results: The OS and EFS in 10 years were 89% and 87%. Survival according to clinical stage as 94.7%,
91.3%, 82.3% and 71% for stages I to IV(p = 0,005). The OS was in 91.3% of patients who received RT and
in 72.6% of patients who did not (p = 0,003). Multivariate analysis showed presence of B symptoms, no
radiotherapy and advanced clinical stage to be associated with a worse prognosis.
Conclusion: This data demonstrating the importance of RT consolidation with low dose and reduced
volume, in all clinical stage of childhood HD, producing satisfactory ten years OS and EFS. As the disease
is highly curable, any data of long term follow-up should be presented in order to better direct therapy,
and to identify groups of patients who would not benefit from radiation treatment.
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Background
During the last two decades, treatment strategies of pedi-
atric Hodgkin's disease have changed considerably. Radi-
otherapy was the standard treatment for limited (stage I or
II) aggressive lymphoma until 1980, although the five-
year rate of disease-free survival was less than 50 percent
[1]. Subsequently, chemotherapy was added to involved-
field radiotherapy (chemo radiotherapy) with the goals of
controlling occult systemic disease and reducing the size
of irradiation fields [2]. Other investigators, however,
showed that chemotherapy alone could cure limited stage
lymphoma [3]; as a result, either chemo radiotherapy or
chemotherapy alone was used for localized disease [4,5].
The vast majority of children with Hodgkin's disease now-
adays have an excellent chance of definite cure [1]. There-
fore the main goal of Hodgkin's disease studies has been
to minimize long-term side effects while maintaining the
high cure rates. Combined chemotherapy and radiother-
apy regimens have become the standard approach
because they allow one to reduce toxicity while maintain-
ing high overall efficacy. In these regimens, chemotherapy
as well as radiotherapy is adapted according to stage,
spread and volume of disease [6-13]. Most treatment pro-
grams for childhood HD consist of combined-modality
therapy, with a focus on reducing the dose and field of
radiation therapy (RT) and the cumulative doses of cyto-
toxic agents [4]. Risk-adapted regimens seek to maintain
disease control while reducing therapy-related complica-
tions. Therefore, this approach may reduce therapy for
patients with favourable diagnostic features or intensify
therapy for patients with unfavourable disease presenta-
tions. Numerous investigations have established that chil-
dren and adolescents with favourable presentations of
Hodgkin's disease are excellent candidates for reduced
therapy. Outcomes for unfavourable patients treated with
contemporary combined-modality or chemotherapy-
alone regimens demonstrate 5-year disease control in the
range of 70% to 90 % [10-13]. In this study we analyze a
single institution's experience of 15 years on the treatment
of childhood Hodgkin's disease.
Methods
Between January 1985 and December 2000 166 patients
younger than 18 years of age were enrolled in this study.
Eligible patients had histologically confirmed Hodgkin's
disease. Patients with unfavourable disease included all
those with Ann Arbor stage III and IV disease, as well as
patients with stage I and II disease who had bulky medi-
astinal lymphadenopathy (defined as the ratio of medias-
tinal mass to intra-thoracic cavity of one third or greater
on upright chest radiograph, or a peripheral lymph node
mass greater than 6 cm in largest diameter), or the pres-
ence of B symptoms. Clinical staging evaluation included
history and physical examination; CBC with differential,
erythrocyte sedimentation rate, routine renal and hepatic
functions and analysis chemistries; chest radiograph, cer-
vical, abdominal, pelvis and thoracic computed tomogra-
phy (CT) scan with contrast and bone marrow biopsy. All
patients included in this sample were submitted to chem-
otherapy. The chemotherapy protocols were modified
according to the institution's current treatment policy dur-
ing the time of this study. The chemotherapy protocols
consisted predominantly of MOPP or ABVD in the period
from 1985 – 1990, ABVD or VEEP between 1990 – 1995
and in the last period ABVD and OPPA + ABVD. Gallium
scan and bone scans were also used to monitor response.
Radiotherapy was restricted to involved fields (IFRT) in a
modified technique in most part of the cases (clinical
stage I-II). The patients with advanced clinical stage (III –
IV) and some patients with stage II (Bulky disease) were
submitted to the upper mantle field. In some cases as clin-
ical stage IV additionally to spleen and para-aortic lymph
nodes received radiation. Visceral sites of involvement
and bone lesions were treated with different doses accord-
ing the organ tolerance. Dose per fraction was 1.8 Gy or 2
Gy, for large volumes in small children 1.5 Gy, using five
sessions per week with final dose between 20 – 30 Gy in
most of cases.
After completion of therapy, patients were followed regu-
larly with physical examination, chest x-ray, and routine
laboratory studies. In addition, restaging studies includ-
ing CT scans of neck, chest, abdomen, and pelvis, and gal-
lium were recommended at 1 and 2 years off therapy.
Additional exams were performed as guided by patients'
symptoms.
Study end points
This study retrospectively analysed 15 years of experience
in the treatment of Hodgkin's disease in childhood. The
primary end point was to evaluate prognosis associated
with the use of radiotherapy on combined treatment and
the real benefit of adjuvant low dose RT in advanced
stages. The secondary objective was to analyse the prog-
nostic factors related to survival (OS) and event free sur-
vival (EFS). The prognostic factors analyzed were: age,
clinical stage, B symptoms, dose radiotherapy, delivery
radiotherapy, chemotherapy, sex and histological sub-
type.
Statistical analysis
EFS were defined as the interval from start treatment to the
date of first event (relapse or progression, second malig-
nancy, or death from any cause) or to the date of last fol-
low-up. Survival was defined as the interval from start
treatment to the date of death from any cause or to last fol-
low-up. EFS and Overall Survival (OS) distributions were
estimated using the Kaplan and Meier method. The log-
rank test was used to examine differences in EFS, OS andRadiation Oncology 2006, 1:38 http://www.ro-journal.com/content/1/1/38
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Cox Regression Test for multivariate analysis of significant
factors. (p < 0.05)
Characteristics of patients and treatment
Demographic characteristics of the patient cohort are
shown in Table 1. The median age was 10 years (range 2.2
– 18 years). The majority of patients were white (n-138,
83.1%); 69.9% were male (n-116). Clinical Stage distribu-
tion was I in 19 patients (11.4%), II in 60 patients
(36.1%), III in 55 patients (33.1%), and IV in 32 patients
(19.1%). B symptoms were present in 112 patients
(67.5%). The median symptoms time until diagnosis was
6 months, the most common manifestation was cervical
lymph node enlargement, seen in 71%. The histology was
nodular sclerosis 48.1%, followed by mixed celularity
34.3%, lymphocyte depletion 1.8 % and lymphocyte pre-
dominant 15.6%. Radiotherapy was delivered to 146
patients (88%). Treatment volumes included mantle field
(34.9%), involved field (43.3%), and para-aortic (5.4%),
or iliac inguinal femoral lymphatics (4.2%). The median
radiation therapy dose was 21 Gy in 1.7 Gy (range 10 – 40
Gy) and distribution of patients submitted to radiother-
apy by dose level was: 10–20 Gy (1.3%), 21 – 30 Gy (98
%) and 31 – 40 Gy (0.7%), as showed in table-2. The
chemotherapy protocols were modified according to the
institution's current treatment policy during time. The
children were treated with ABVD in 39% (n-65) of the
cases, by VEEP in 13 %(n-22), MOPP in 13 %(n-22),
OPPA-13 %(n-22) and ABVD/OPPA in 22 %(n-33). The
distribution of fields radiotherapy, doses radiotherapy
and chemotherapy protocols used in treatment of patients
according to clinical stage is displayed in table-3. All the
patients with initial clinical stage (I – II) received radio-
therapy with dose less or equal than 21 Gy. Involved field
and mantle field radiotherapy was delivery to 72/146
(43.3%) and 58/146 (35%) of patients, respectively.
Involved field radiotherapy was used in 62/75 (82.4%) of
initial clinical stage (I-II) patients as showed in table-3.
Results
Overall survival and event free survival rates
The median follow-up for living patients was 109 months
(10–237 months). Five and ten-years overall survival was
90.3% and 89%, respectively (fig 1). Five and 10-years EFS
was 88.5% and 87%, respectively (fig 2). The ten years
overall survival for clinical stage was: I (94.7%), II
(91.3%), III (82.6%), and IV (71%) (p = 0.005). figure 6
Prognostic factors
The results of the univariate analyses of the prognostic fac-
tors for EFS and OS are shown in Table 3. The significant
prognostic factors associated unfavorable OS were: Age
less than ten years(p = 0.01), no radiotherapy(p = 0.003),
presence B symptoms (p = 0.0001) and clinical stage(p =
Table 2: characteristics of treatment
Radiotherapy Number (%)
146 (88)
RT/clinical stage
I 17 (10.2)
II 58 (34,9)
III 45 (27,1)
IV 26 (15,6)
RT dose Median (Gy) Range (Gy)
21 10–40
RT/level dose Gy Number (%)
10 – 20 Gy 2 (1.3)
21 – 30 Gy 143 (98)
31 – 40 Gy 1 (0.7)
RT field Number (%)
Involved field 72 (43,3)
Mantle field 58 (34,9)
Infradiafragmatic field 9 (5,4)
Total nodal irradiation 7 (4,2)
Chemotherapy Number (%)
ABVD 65 (39)
VEEP 22 (13)
MOPP 22 (13)
OPPA 33 (22)
OPPA +ABVD 22 (13)
Table 1: Patients characteristics
Age Median (Y) Range
10 2.2 – 18
Sex Male (%) Female (%)
116 (69.9) 50 (30.1)
Race White (%) Black (%)
138(83.1) 28 (16.9)
Symptoms time Median (M) Range (M)
61 – 1 2
Clinical stage Number(%)
I 19 (11.7)
II 60 (36.1)
III 55 (33.1)
IV 32 (19.1)
Histology Number (%)
Sclerosis nodular 80(48.1)
Mixed celullarity 57(34.3)
Lymphocitic depletion 26(15.6)
Predominant lymphocitic 3 (1.8)
Symptoms B Number (%)
Present 112 (67.5%)
Absent 54 (32.5%)Radiation Oncology 2006, 1:38 http://www.ro-journal.com/content/1/1/38
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0.005)(figure 4, 5, 6, 7). Multivariate analysis revealed
independent unfavorable prognostic factors for OS:
advanced clinical stage (p = 0.02, HR = 9.2, IC95%-1.3 –
4.3), no radiotherapy (p = 0.03, HR = 4.3, IC95% – 1.2–
9), and presence B symptoms. (p = 0.001, HR = 11, IC95%
– 2–16.8) in table-5. The overall survival did not differ for
patients treated with radiation therapy dose major than
21Gy (p = 0.75), sex (p = 0.6), mediastinuminvolvement
(p = 0.66) or the schedule of chemotherapy (p = 0.27)
done in the period of study did not influenced survival, as
demonstrated table-4
Outcome in unfavorable risk subgroups
Using the three unfavorable independent prognostic fac-
tors for OS, the patients were divided into three risk
groups to calculate the OS at five years (Fig. 3). For
patients with no adverse prognostic factors (n = 52) the
OS was 96%, for patients with one adverse prognostic fac-
tors (n = 98) the OS was 84.6% and for patients with two
or more adverse prognostic factors (n = 11) OS was 71.6%
(p = 0.002). The curves of overall survival for unfavorable
prognostic factors are shown in figure 3.
overall survival curves of unfavorable prognostic factors (log- Rank Test) Figure 3
overall survival curves of unfavorable prognostic factors (log-
Rank Test).
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Table 3: Radiotherapy Dose, Fields and chemotherapy according 
clinical stage.
Radiotherapy 146 (88)
Clinical Stage
RT/clinical stage II I I I I I V
17 58 45 26
Dose RT Gy II I I I I I V
< = 21 Gy 17 58 44 26
> 21 Gy 0 0 **1 0
RT field II I I I I I V
Involved field 17 45 8 2
Mantle field 0 13 35 10
Infradiafragmatic field 0 0 2 7
Total nodal irradiation 0 0 0 7
Chemotherapy II I I I I I V
ABVD 17 45 1 0
VEEP 0 13 9 0
OPPA 2* 2* 16 2
MOPP 0 5* 17 0
ABVD/OPPA 0 5* 2 30
*patients submitted to chemotherapy alone
** patients received 40 Gy
overall survival (Kaplan Meier estimative) Figure 1
overall survival (Kaplan Meier estimative).
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Second tumors
The incidence of second tumors was 1.8% (three cases) in
fifteen years of follow-up. The cases of second tumors
included two cases of thyroid carcinoma and one case of
breast cancer. All cases were treated conformed protocols
by cancer site.
Discussion
Treatment of Hodgkin's disease usually combines chemo-
therapy (CT) and low dose radiation (RT) to obtain best
results [14-23]. The rationale for this procedure is that
while chemotherapy eradicates disseminated subclinical
disease and small burden nodal disease, radiotherapy is
considered necessary to improve local control and
enhance duration of response of bulky lymphomas. The
combination of both treatment modalities allows one to
reduce the intensity and duration of chemotherapy as well
as the dose and volume of RT. Early stage disease (I to IIA)
presents excellent results with either combined treatment
or chemotherapy alone, with DFS or EFS in excess of 90%
[24]. In this cohort ten year OS and EFS was 94.5% and
93%, respectively, for clinical stage I and II. These data are
compatible with other published results. The German-
Austrian group carried out three studies with different RT
doses schedules. In the HD90 study 25, 25, and 20 Gy was
used in stages I-IIA, IIB-IIIA, and IIIB-IV, respectively,
depending on the duration of chemotherapy; EFS among
patients with localized disease was 92% to 96% [24]. The
role of additional RT in stage III or IV disease remains con-
troversial. Advanced disease (III to IV) requires more
aggressive therapy. Subsequent trials from international
study groups have obtained higher overall and disease-
overall survival curves for clinical stage (log – Rank Test) Figure 7
overall survival curves for clinical stage (log – Rank Test).
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overall survival curves for B symptoms presence (log- Rank 
Test).
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free survival rates, by increasing the dose intensity of treat-
ment. Contemporary CMT trials report 5-year EFS rates
greater than 80% in advanced disease. Chemotherapy and
RT to bulky or residual disease provide a 10-year progres-
sion-free survival (PFS) or EFS of only 38% to 49% in
stage IV [25,26]. Hybrid regimens using ABVD/ABV alter-
nating with MOPP/COPP provide disease control in
about 75% of stage IIB-IV patients without RT [27] but
stage IV patients perform poorly with such conventional
therapy, even if additional IFRT is administered: In our
study patients with advanced stage IV obtained satisfac-
tory OS and EFS in ten years 71 % and 69%, respectively.
Our data suggest that advanced stage IV requires more
aggressive therapy and radiotherapy has improved overall
survival and event free survival rates. In the last decade,
two major pediatric trials [28,29] have evaluated the util-
ity of Low dose -IFRT in the treatment of Hodgkin's lym-
phoma. A trial of the former Children's Cancer Group
(CCG) for children and adolescents with Hodgkin's lym-
phoma compared outcome in patients who achieved an
initial complete response with chemotherapy followed by
Low dose-IFRT or no further therapy. Complete response
was defined as an absence of residual tumor or residual
tumor that showed a reduction in size of 70% or more
since diagnosis and a change from gallium positivity [28]
Patients received risk-adapted chemotherapy (stages I-III,
COPP/ABV; stage IV, more intensive therapy). The EFS for
the 829 eligible patients was 85% at 5 years. Complete
response was obtained in 83% of patients. Five hundred
Table 5: multivariate analyses of unfavourable significant factors 
for OS*
Variable p HR 95% confidential interval
Age > 10 years 0.06 3.3 0.9 18.3
Present B Symptoms 0.001 11 2.07 16.8
No Radiotherapy 0.03 4.3 1.2 9
Advanced Clinical 
stage
0.02 9.2 1.3 4.3
*Cox Regression estimate, HR = hazard Risk
Table 4: Univariate analysis of prognostic factors for Os and EFS*
VARIABLE
Age number % Five years OS % EFS% OS p EFS p
> 10 56 33.8 97.8 94.2 0.01 0.06
< 10 110 66.2 86.6 89.4
Sex
Female 116 69.8 89.4 96 0.84 0.6
Male 50 30.2 92.9 87
Histology
Ns 80 48.1 93 95 0.08 0.21
Mc 57 34.3 86.4 90
Lp 26 15.6 98 80.4
Dl 3 1.8 88.6 87
Stage
I 19 11.7 94.5 93 0.005 0.02
II 60 36.4 91 91
III 55 32.1 82.5 80
IV 32 19.8 71 69
Radiotherapy
Yes 146 87.9 91 94 0.003 0.07
No 20 12.1 72 88
RT dose
= < 21 GY 112 79.6 92.5 88.4 0.76 0.5
>21 Gy 34 20.4 89.1 90.2
Chemotherapy
ABVD 66 40,9 90.4 91 0.16 0.15
MOOP 22 13,6 92.6 88
VEEP 17 10,5 90.7 91.2
OTHERS 56 34,7 88.8 86
Symptoms B
Present 114 68.7 77.4 69.5 0.0001 0.0001
Absent 52 31.3 97.3 96.4
Mediast involved
Present 16 9.7 90 89 0.7 0.5
Absent 150 90.3 92.9 91
* Kaplan Meier and log – Rank TestRadiation Oncology 2006, 1:38 http://www.ro-journal.com/content/1/1/38
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and one patients were randomized to receive low dose -
IFRT or no further therapy. In an as-treated analysis, 3-
year EFS was 93% for patients receiving Low dose -IFRT,
and 85% for patients receiving no further therapy. Three-
year survival for patients treated with and without low
dose -IFRT was 98% and 99%, respectively [28]. The Ger-
man Pediatric Oncology and Hematology Group (GPOH)
initiated a study to assess the effect on EFS and OS of elim-
inating radiation for all patients achieving complete reso-
lution of disease following chemotherapy [29]. Overall
EFS was 92% for patients receiving radiation and 88% for
those receiving no radiation (P = .05). In both the German
GPOH-95 and CCG-5942 studies, the benefit of radiation
therapy on EFS was greater in patients with advanced-
stage disease at presentation.
In our institution in the period analyzed (1985–2000),
IFRT was defined as treatment volume including the ini-
tially involved lymph node region(s) and 82.4% of initial
clinical stage(I-II) patients in this series was treated with
this volume of radiotherapy. Field definition for radiation
therapy in unfavorable, and advanced Hodgkin's lym-
phoma was variable and protocol dependent. Although
IFRT remained the standard when patients were treated
with combined modality therapy, restricting radiation
therapy to areas of initial bulk disease was possible to be
used in 15% of the cases (stage III and IV) and in other
cases mantle and extend fields were used mainly in stage
III and IV (85%).
Protocols with MOPP chemotherapy (or derivatives)
alone use higher cumulative doses of alkylating agents
than CMT, and are associated with an increased risk of
infertility and a higher cumulative risk of leukemia
(7.9%) at 15 years after chemotherapy alone than after
CMT (3.4%), as shown by the Late Effects Study Group
[29,30]. The incidence in this cohort of second tumors
was 1.8% (three cases) in fifteen years of follow-up. The
cases of second tumors included two cases of thyroid car-
cinoma, one case of breast cancer and no cases of leuke-
mia were seen. This data could be explained by the small
number of patients who used high cumulative doses of
MOOP and etoposide (23%). But indeed, long term fol-
low-up of patients treated for HD in childhood shows a
18.5-fold increased risk of developing a second malignant
neoplasm, mainly radiation-associated solid tumors
(breast and thyroid cancers)[31].
Most publications in childhood HD have identified vari-
ous prognostic factors. In the German Pediatric Oncology
and Hematology Group (GPOH) GPOH-95 study, B
symptoms, histology, and male sex were adverse prognos-
tic factors for event-free survival on multivariate analysis
[29]. In 320 children with clinically staged Hodgkin's
lymphoma treated in the Stanford-St. Jude-Dana Farber
Cancer Institute consortium, male gender; stage IIB, IIIB,
or IV disease; white blood cell count 11,500/mm3 or
higher; and hemoglobin lower than 11.0 g/dL were signif-
icant on multivariate analysis for inferior disease-free sur-
vival and overall survival. Prognosis was associated with
the number of adverse factors [32]. In the CCG-5942
study, the combination of B symptoms and bulky disease
was associated with an inferior outcome [28,31,33,34]. In
our analysis radiotherapy administration, early clinical
stage, no B symptoms, were independent associated with
improved overall survival. The prognostic factors associ-
ated with improved EFS were female gender, clinical stage,
absent B symptoms and age less than ten years. These fac-
tors revealed that more efforts are still required in order to
improve long-term survival in unfavorable and advanced
disease as well as relapsed cases. Radiotherapy has a
potential role in advanced Hodgkin's lymphoma reducing
relapses in initially involved sites and improving survival.
Conclusion
This data demonstrating the importance of RT consolida-
tion with low dose and reduced volume, in all clinical
stage of childhood HD, producing satisfactory ten years
OS and EFS. Our results, though retrospective, suggests
that patients who were able to receive RT performed better
and were expected to achieve better local control when
compared to patients whom for any reason were not able
to undergo RT. As the disease is highly curable, any data
of long term follow-up should be presented in order to
better direct therapy, and to identify groups of patients
who would not benefit from radiation treatment.
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